Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Free Cash Flow: 2014-2024

Historic Free Cash Flow for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to -$176.7 million.

  • Cidara Therapeutics' Free Cash Flow fell 10.61% to -$40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.9 million, marking a year-over-year increase of 16.99%. This contributed to the annual value of -$176.7 million for FY2024, which is 670.21% down from last year.
  • Cidara Therapeutics' Free Cash Flow amounted to -$176.7 million in FY2024, which was down 670.21% from -$22.9 million recorded in FY2023.
  • Cidara Therapeutics' 5-year Free Cash Flow high stood at -$22.9 million for FY2023, and its period low was -$176.7 million during FY2024.
  • Its 3-year average for Free Cash Flow is -$76.1 million, with a median of -$28.6 million in 2022.
  • Per our database at Business Quant, Cidara Therapeutics' Free Cash Flow spiked by 53.64% in 2021 and then plummeted by 670.21% in 2024.
  • Yearly analysis of 5 years shows Cidara Therapeutics' Free Cash Flow stood at -$54.6 million in 2020, then soared by 53.64% to -$25.3 million in 2021, then declined by 12.96% to -$28.6 million in 2022, then climbed by 19.78% to -$22.9 million in 2023, then crashed by 670.21% to -$176.7 million in 2024.